Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Mithat Gönen, Zhuoxin Sun, Maria E. Figueroa, Jay P. Patel, Omar Abdel-Wahab, Janis Racevskis, Rhett P. Ketterling, Hugo Fernandez, Jacob M. Rowe, Martin S. Tallman, Ari Melnick, Ross L. Levine, Elisabeth Paietta

Blood (2012) 120 (11): 2297–2306.

https://doi.org/10.1182/blood-2012-02-414425

Published: 2012

Includes: Supplemental data

Journal Articles

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Janelle Perkins, PharmD, Jongphil Kim, PhD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD, Ernesto Ayala, MD, Lia Perez, MD, Hugo Fernandez, MD, Karen Fancher, PharmD, Cheryl Tate, PharmD, Teresa Field, MD

Blood (2009) 114 (22): 3347.

https://doi.org/10.1182/blood.V114.22.3347.3347

Published: 2009

Journal Articles

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Maria E. Figueroa, Lucy Skrabanek, Yushan Li, Anchalee Jiemjit, Tamer E. Fandy, Elisabeth Paietta, Hugo Fernandez, Martin S. Tallman, John M. Greally, Hetty Carraway, Jonathan D. Licht, Steven D. Gore, Ari Melnick

Blood (2009) 114 (16): 3448–3458.

https://doi.org/10.1182/blood-2009-01-200519

Published: 2009

Includes: Supplemental data

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine.

Teresa Field, MD, PhD, Melissa Alsina, MD, Ernesto Ayala, MD, Hugo Fernandez, MD, William Janssen, PhD, Mohammed Karfan-Dabaja, MD, Jeffery Lancet, MD, Mafda Melchert, MD, Jyoti Raychaudhuri, MD, Daniel Sullivan, MD, Alan List, MD, Claudio Anasetti, MD, William Poling, PhD, Janelle Perkins, PharmD

Blood (2007) 110 (11): 5035.

https://doi.org/10.1182/blood.V110.11.5035.5035

Published: 2007

Journal Articles

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Todd Alekshun, MD, Christine Mcisaac-Simonelli, RN, Mohamed Kharfan-Dabaja, MD, William Dalton, MD, PhD, Benjamin Djulbegovic, MD, Hugo Fernandez, MD, Daniel M. Sullivan, MD, Ernesto Ayala, MD, Teresa L. Field, MD, Dawn Garrett, LPN, William E. Janssen, PhD, Beth Maddox, RN, Lia Perez, MD, Dawn Kettner, PA, Janelle Perkins, PharmD, Jyoti Raychaudhuri, MD, Claudio Anasetii, MD, Melissa Alsina, MD

Blood (2007) 110 (11): 5131.

https://doi.org/10.1182/blood.V110.11.5131.5131

Published: 2007

Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD

Blood (2007) 110 (11): 943.

https://doi.org/10.1182/blood.V110.11.943.943

Published: 2007

NARROW

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine.

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine.

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only